Welcome to our dedicated page for NextCure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextCure, Inc. filings document a clinical-stage oncology issuer's financial reporting, governance, capital structure, and material-event disclosures. Recent Form 8-K reports furnish quarterly and annual results, business update exhibits, Regulation FD materials on ADC programs, officer transition disclosure, a completed private placement of common stock and pre-funded warrants, and an effected reverse stock split.
The company's proxy materials cover annual meeting matters including director elections, auditor ratification, say-on-pay, board governance, and executive compensation for a Delaware corporation with Nasdaq-listed common stock.
NextCure, Inc. director Ellen Feigal received a grant of stock options covering 2,340 shares of common stock. These options have an exercise price of $2.02 per share and expire on June 17, 2036.
The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 Annual Meeting of Stockholders. Following this grant, Feigal holds 2,340 stock options directly related to this award.
NextCure, Inc. director Anne Elizabeth Borgman reported a grant of stock options covering 2,340 shares of common stock at an exercise price of $2.02 per share. The option vests in full on the earlier of June 18, 2027 and the 2027 Annual Meeting of Stockholders and expires on June 17, 2036. Following this grant, she holds 2,340 options directly.
NextCure, Inc. director Stephen W. Webster reported receiving a stock option grant covering 2,340 shares of common stock. The option has an exercise price of $2.02 per share and expires on June 17, 2036. It vests in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Stockholders, and reflects equity compensation rather than an open-market purchase or sale.
NextCure, Inc. director David S. Kabakoff received a stock option grant giving him the right to buy 3,510 shares of common stock at an exercise price of $2.02 per share as compensation. Following this award, he holds stock options for 3,510 shares directly.
The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 annual stockholders’ meeting, meaning it becomes exercisable at that time. The option expires on June 17, 2036, providing a long-dated incentive tied to the company’s future performance.
NextCure, Inc. director John G. Houston reported a grant of stock options representing 2,340 shares of common stock. These options have an exercise price of $2.0200 per share and expire on June 17, 2036.
The option vests in full on the earlier of June 18, 2027 and the date of NextCure’s 2027 Annual Meeting of Stockholders, making this a routine, compensation-related award rather than an open-market purchase or sale. Following this grant, Houston holds options for 2,340 shares directly.
NextCure, Inc. reported Phase 1 dose escalation data for its investigational ADC SIM0505 in advanced solid tumors, with a focus on gynecologic cancers. The study enrolled 59 heavily pre-treated patients in the U.S. and China at doses from 1.6 mg/kg to 9.6 mg/kg without CDH6 preselection.
Among 20 gynecologic cancer patients in therapeutic dose cohorts of 4.8–8.0 mg/kg with at least 12 weeks of follow-up, the objective response rate was 55% (11/20). Ovarian cancer patients (n=17) had a 52.9% ORR (9/17), and uterine serous carcinoma patients (n=3) had a 66.7% ORR (2/3), based on RECIST 1.1.
In 59 patients, treatment-emergent adverse events were mainly hematologic, nausea and vomiting; grade 3–4 events were predominantly hematologic and described as manageable without primary prophylaxis. Dose discontinuations were linked to interstitial lung disease, fungal pneumonia and thrombocytopenia at higher doses. NextCure stated that its existing cash, cash equivalents and marketable securities are expected to fund planned operations into the first quarter of 2027.
NextCure, Inc. reporting persons SilverArc Capital Management, LLC and Devesh Gandhi each disclose beneficial ownership of 176,057 shares of Class A Common Stock, representing 4.94% of the class. The filing shows shared voting and shared dispositive power over those shares. The filing is signed on 05/13/2026.
NextCure, Inc. reported a net loss of $9.8 million for the quarter ended March 31, 2026, modestly improved from $11.0 million a year earlier, as both research and development and general and administrative expenses declined.
Operating expenses fell to $10.1 million, driven by lower spending on deprioritized programs and reduced stock-based compensation, partly offset by new costs for SIM0505, an antibody-drug conjugate licensed in 2025. Other income decreased as interest earnings declined with a smaller cash balance.
Cash, cash equivalents and marketable securities totaled $29.7 million, and operating activities used $13.4 million of cash in the quarter. The company disclosed that this cash is not sufficient to fund operations for 12 months after issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern unless additional capital is secured. NextCure continues Phase 1 trials for SIM0505 and LNCB74 and raised about $1.2 million through at-the-market stock sales during the quarter.
NextCure, Inc. reported first quarter 2026 results and highlighted pipeline progress. The FDA granted Fast Track designation to SIM0505 for platinum-resistant ovarian cancer, and initial Phase 1 dose escalation data are expected in Q2 2026, with a planned ASCO 2026 presentation.
Management is expanding SIM0505 development by increasing U.S. trial sites and moving into Canada and Europe, while Phase 1 enrollment continues for the LNCB74 B7-H4 antibody-drug conjugate. For the quarter ended March 31, 2026, research and development expense was $6.8M and general and administrative expense was $3.3M.
Net loss was $9.8M, or $1.87 per share, compared with a $11.0M loss, or $4.70 per share, a year earlier. Cash, cash equivalents and marketable securities totaled $29.7M as of March 31, 2026.
NextCure, Inc. Schedule 13G/A Amendment discloses that a group of related Simcere entities and two individuals report beneficial interests totaling 338,636 shares of NextCure common stock, representing 9.4% of the class, based on 3,607,555 shares outstanding as of April 22, 2026. The filing is a joint amendment by Simcere Zaiming, Inc.; Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Pharmaceutical Group Limited; and Messrs. Ren and Tang, and includes a standard disclaimer that each Reporting Person disclaims beneficial ownership except for pecuniary interest.